Soleno Therapeutics (SLNO) Enterprise Value: 2013-2019
Historic Enterprise Value for Soleno Therapeutics (SLNO) over the last 6 years, with Dec 2019 value amounting to $131.3 million.
- Soleno Therapeutics' Enterprise Value rose 868.59% to $131.3 million in Q4 2019 from the same period last year, while for Dec 2019 it was $131.3 million, marking a year-over-year increase of 643.82%. This contributed to the annual value of $1.9 billion for FY2024, which is 57.88% up from last year.
- As of Q4 2019, Soleno Therapeutics' Enterprise Value stood at $131.3 million, which was up 260.06% from $36.5 million recorded in Q3 2019.
- Over the past 5 years, Soleno Therapeutics' Enterprise Value peaked at $131.3 million during Q4 2019, and registered a low of $904,014 during Q4 2017.
- Over the past 3 years, Soleno Therapeutics' median Enterprise Value value was $28.4 million (recorded in 2017), while the average stood at $36.1 million.
- As far as peak fluctuations go, Soleno Therapeutics' Enterprise Value spiked by 19,036.85% in 2015, and later tumbled by 91.00% in 2017.
- Over the past 5 years, Soleno Therapeutics' Enterprise Value (Quarterly) stood at $17.4 million in 2015, then slumped by 42.24% to $10.0 million in 2016, then tumbled by 91.00% to $904,014 in 2017, then skyrocketed by 1,399.44% to $13.6 million in 2018, then spiked by 868.59% to $131.3 million in 2019.
- Its last three reported values are $131.3 million in Q4 2019, $36.5 million for Q3 2019, and $73.5 million during Q2 2019.